Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of subcutaneous Remsima in active ankylosing spondylitis
KCT0008747Phase 4Recruiting
- Sponsor
- Celltrion
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab in ankylosing spondylitis (AS), sponsored by Celltrion. Started Feb 2023; status: recruiting.
02
Drugs
infliximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on KCT0008747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008747.